Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 08.03.2024 17:29:59
Thrombogenics NV (THR.F, Frankfurt)
Závěr k 28.3.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
0,0001 0,00 0,00 550
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiOxurion NV
TickerOXUR
Kmenové akcie:Ordinary Shares
RICOXUR.BR
ISINBE0003846632
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.06.2023
Počet zaměstnanců k 31.12.2022 27
Akcie v oběhu k 05.03.20245 753 951 723
MěnaEUR
Kontaktní informace
UliceGaston Geenslaan 1
MěstoLEUVEN (LOUVAIN)
PSČ3001
ZeměBelgium
Kontatní osoba 
Funkce kontaktní osoby 
Telefon3 216 751 310
Fax3216751311

Business Summary: Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Oxurion NV revenues decreased 31% to EUR180K. Net loss decreased 27% to EUR10.6M. Revenues reflect Sales decrease of 30% to EUR124K, Income from royalties decrease of 33% to EUR56K. Lower net loss reflects Research and development expenses decrease of 41% to EUR5.6M (expense), General and administrative expenses decrease of 35% to EUR2.3M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Chief Financial Officer, DirectorPascal Ghoson-29.12.202329.12.2023
Chief Legal Officer and Compliance Officer, Member of the Executive CommitteeKathleen Paisley-01.01.2020
Chief Business Officer, Company Secretary, Member of the Executive CommitteeMichael Dillen-
Chief Development Officer, Member of the Executive CommitteeAndy De Deene-